The Market Reports

Synopsis
The global market for Dry Eye Syndrome was estimated to be worth US$ 5877 million in 2024 and is forecast to a readjusted size of US$ 7963 million by 2031 with a CAGR of 4.5% during the forecast period 2025-2031.
This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Dry Eye Syndrome cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry eyes. Other associated symptoms include irritation, redness, discharge, and easily fatigued eyes. Blurred vision may also occur. The symptoms can range from mild and occasional to severe and continuous. Scarring of the cornea may occur in some cases without treatment. In this report, we mainly study the drugs and eye drops for dry eye.
The Dry Eye Syndrome market is driven by the rising prevalence of dry eye conditions globally, fueled by aging populations, increased screen time, and lifestyle-related factors. The widespread use of digital devices has significantly contributed to eye strain and reduced blink rates, leading to a surge in dry eye cases, especially among younger demographics. Additionally, growing awareness of ocular health and improved diagnosis through advanced diagnostic tools have increased patient identification and treatment rates. The introduction of innovative therapies, including anti-inflammatory eye drops, tear-stimulating drugs, and device-based treatments, is also expanding the market landscape.
Despite growing demand, the Dry Eye Syndrome market faces several challenges, including underdiagnosis, variable symptoms, and limited long-term treatment efficacy. Many patients remain undiagnosed due to the overlap of symptoms with other ocular conditions and the subjective nature of the disease. Current treatments often offer only temporary relief rather than a cure, leading to poor adherence and patient dissatisfaction. Moreover, the development of new therapies is hindered by the complex pathophysiology of the condition, which involves both aqueous and evaporative components. Addressing these challenges requires improved diagnostic criteria, personalized treatment approaches, and increased investment in research and clinical trials.
Global Dry Eye Syndrome key players include Allergan, Alcon, Novartis, Santen Pharma, Johnson & Johnson, etc. Global top five manufacturers hold a share over 60%. North America is the largest market, with a share over 55%, followed by Europe and Asia-Pacific, both have a share over 35 percent. In terms of product, Anti-inflammatory Drugs is the largest segment, with a share over 50%. And in terms of application, the largest application is Hospital, followed by Retail Pharmacy.
This report aims to provide a comprehensive presentation of the global market for Dry Eye Syndrome, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Dry Eye Syndrome by region & country, by Type, and by Distribution Channel.
The Dry Eye Syndrome market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dry Eye Syndrome.
Market Segmentation
By Company
AbbVie
Alcon
Novartis
Santen Pharma
Johnson & Johnson
Bausch & Lomb
Thea pharmaceuticals
URSAPHARM
SIMILASAN
Akorn
United Laboratories
Sun Pharmaceutical
Jianfeng Group
OmniVision Pharma
Rohto
Prestige Consumer Healthcare
LION
Kenvue (VISINE)
Segment by Type
Artificial Tears
Anti-inflammatory Drugs
Others
Segment by Distribution Channel
Hospital
Retail Pharmacy
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Dry Eye Syndrome manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Distribution Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Dry Eye Syndrome in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Dry Eye Syndrome in country level. It provides sigmate data by Type, and by Distribution Channel for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index